Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Trajenta Duo 2.5mg/850mg Tablet is a powerful combination designed to regulate elevated blood sugar levels in individuals grappling with type 2 diabetes mellitus. This dynamic duo not only aids in averting severe complications like kidney damage, vision impairment, but also mitigates the risk of heart attacks and strokes.
This medication, comprising metformin and linagliptin, can be prescribed independently or in conjunction with other diabetes medications. The optimal outcomes are achieved when complemented with a balanced diet and regular exercise. Your prescribed dosage will be tailored to your specific condition, blood sugar levels, and concurrent medications. Consuming this tablet with meals is advised to minimize the likelihood of an upset stomach.
Medical Uses:
Trajenta Duo Tablet for Type 2 Diabetes Mellitus
Key Advantages:
Unlock the Benefits of Trajenta Duo Tablet in Managing Type 2 Diabetes
Trajenta Duo 2.5mg/850mg Tablet harnesses the synergistic effects of metformin and linagliptin. Metformin, a potent biguanide, operates by suppressing glucose production in the liver, delaying glucose absorption from the intestines, and enhancing the body's insulin sensitivity. Linagliptin, a DPP-4 inhibitor, promotes insulin release from the pancreas while diminishing blood sugar-elevating hormones. This dual action ensures better control over blood glucose levels, reducing the risk of complications such as kidney damage, vision issues, neuropathy, and limb loss. Moreover, maintaining optimal diabetes management contributes to a lower risk of cardiovascular issues.
Adhering to a consistent regimen of Trajenta Duo, combined with a balanced diet and regular exercise, fosters a pathway to a normal, healthy life. Committed usage is vital for safeguarding future health.
Mechanism of Action:
Understanding How Trajenta Duo Works
Trajenta Duo 2.5mg/850mg Tablet integrates the robust antidiabetic properties of Metformin and Linagliptin. Metformin's role involves reducing glucose production in the liver, delaying intestinal glucose absorption, and heightening insulin sensitivity. Linagliptin, as a DPP-4 inhibitor, enhances insulin release from the pancreas while curbing blood sugar-elevating hormones. This combined mechanism results in improved control over fasting and postmeal sugar levels, offering comprehensive blood sugar management.
Explore Amoha Trajenta Duo 2.5mg/850mg:
Embrace the Future of Diabetes Management with Amoha Trajenta Duo 2.5mg/850mg, Featuring Fi-coated Tablets